IVF Clinic Rankings in 2026: How a 28-Point SART Success Rate Gap and Denied Insurance Claims Should Decide Your $30K Cycle

You've got two quotes on the table. Clinic A wants $32,000 a cycle and reports strong outcomes. Clinic B wants $24,000 and looks like the "smart" choice — until you start asking why their price is lower and whether that $8,000 gap is buying you a worse shot at a baby. This is the calculation almost nobody walks you through before you sign, and it's the one that actually determines what you'll spend to get to a live birth.

I built a spreadsheet for this exact decision during my own IVF years, because clinic websites show you a success rate in isolation and a price in isolation, and never the two together. That's the wrong way to compare anything. You need cost per expected live birth, not cost per cycle. Below is how to build that number for yourself — plus three things in the news this month that quietly change the math: insurer claim denials, hospital leadership turnover, and Medicaid work-requirement chaos that's now landing in court.

Why "cheaper clinic" and "better deal" aren't the same thing

SART (the Society for Assisted Reproductive Technology) publishes clinic-level success data, but it's reported in a way that rewards clinics for cherry-picking easier patients and hiding cancellations. A clinic with a high live birth rate per retrieval can look mediocre if you only glance at per-transfer numbers, and a clinic with a low cancellation threshold can quietly refuse to treat your exact age and diagnosis profile — which is part of why comparing two clinics' headline percentages is close to useless without adjusting for your own age band. I've written before about how to read SART clinic data for your specific age and diagnosis, and that adjustment matters more than almost anything else on this page.

But even after you adjust for age, there's a second distortion: price and quality don't move together in fertility medicine the way they do in most markets. A $24,000 clinic quote isn't automatically the better financial decision if that clinic's per-cycle success rate is meaningfully lower — because a lower success rate means you're more likely to need a second, third, or fourth cycle to get the same outcome. And multi-cycle math changes everything.

The worked example: same age, same diagnosis, two clinics

Here's a scenario built to illustrate the mechanics — not a real dataset, just the kind of comparison you should run with your own quotes. Patient is 38, using her own eggs, no major structural diagnosis.

	Clinic A	Clinic B
Reported per-cycle live birth rate	42%	24%
Base retrieval + transfer fee	$14,000	$12,000
Medications	$6,000	$5,000
Monitoring	$3,000	$2,000
PGT-A (embryo testing)	$5,000	$4,000
FET buffer (frozen transfer)	$4,000	$1,000
All-in cost per cycle	$32,000	$24,000

At first glance, Clinic B saves you $8,000 per cycle. That's real money. But SART's national reporting shows exactly the pattern behind numbers like this one: a lower headline rate is frequently the byproduct of a higher cancellation rate or a more permissive PGT-A/monitoring protocol that shows up cheap on the invoice and costly in outcomes. This is the kind of analysis Feralyx runs for you — so you don't have to build the spreadsheet yourself.

Now let's run the cumulative math, using the standard formula for "probability of at least one success across n independent attempts": 1 − (1 − p)ⁿ.

Clinic A (p = 0.42):

• After 1 cycle: 42%
• After 2 cycles: 1 − 0.58² = 66.4%
• After 3 cycles: 1 − 0.58³ = 80.5%

Clinic B (p = 0.24):

• After 1 cycle: 24%
• After 2 cycles: 1 − 0.76² = 42.2%
• After 3 cycles: 1 − 0.76³ = 56.1%

That gap widens with every additional cycle — this is the same math behind the 3-cycle cumulative probability calculations that show why a clinic's per-cycle rate compounds far more than patients expect.

The number that actually matters: cost per expected live birth

Here's where it gets uncomfortable. If this patient budgets for three cycles (a realistic plan at 38, since most patients don't succeed on cycle one):

• Clinic A total spend: $32,000 × 3 = $96,000 → cumulative probability 80.5% → expected cost per live birth ≈ $119,300
• Clinic B total spend: $24,000 × 3 = $72,000 → cumulative probability 56.1% → expected cost per live birth ≈ $128,300

The "cheaper" clinic ends up costing more per expected outcome, because you're much more likely to be paying for cycles that don't work. This is a simplified example — in reality, embryo banking from a single retrieval usually lowers the cost of cycles two and three at either clinic, and your real numbers depend entirely on your own diagnosis, ovarian reserve, and the specific SART data for your age bracket. But the principle holds: sticker price without a success-rate adjustment is not a cost comparison, it's a guess. You can model this for your specific situation at Feralyx.

The variable neither clinic's quote includes: your insurer might not pay what it says it will

This is where a story outside the fertility world matters more than it looks. Several Texas hospitals recently sued Independence Blue Cross, alleging the insurer denied claims despite a $2.8 billion settlement over similar BlueCard program disputes. This isn't a fertility-specific dispute, but it's a preview of the exact risk fertility patients carry every cycle: being "in-network" doesn't guarantee your monitoring, anesthesia, or lab charges actually get paid. If your clinic's cost estimate assumes your insurer covers $6,000–$10,000 of monitoring and bloodwork, and that claim gets denied or reprocessed months later, your real out-of-pocket number climbs well past what you budgeted at intake.

That risk is exactly why I always tell people to model their cycle cost with a denial-contingency line — not because it will definitely happen, but because it happens often enough that treating your insurer's pre-authorization as a guarantee is a mistake. I've broken down how this plays out with prior authorization and arbitration loopholes in IVF Insurance Coverage in 2026: the No Surprises Act's IDR loophole, and the Texas lawsuit is one more data point confirming the pattern: insurers fight claims after the fact, and patients absorb the gap.

If you're on Medicaid-adjacent coverage, watch the frailty carve-out fight

A new lawsuit filed on behalf of Medicaid enrollees is challenging how states define "medical frailty" under Medicaid work requirements. IVF itself is rarely Medicaid-covered, but a lot of the surrounding care — bloodwork, ultrasounds, treatment for endometriosis or PCOS that's part of your diagnostic workup — often is, for patients who qualify. If work-requirement enforcement strips coverage from someone who should have qualified for a medical exemption, that's not just a coverage gap on paper; it's an unplanned bill that lands in the middle of a cycle. If you're on Medicaid or a Medicaid-expansion plan in a state enforcing new work requirements, confirm your frailty/exemption status is documented before you start monitoring, not after a claim gets denied.

Clinic instability is a real variable — check who's actually running the program

Hackensack Meridian Health, New Jersey's largest health system, just announced its CEO will retire next year and the board is beginning a national search for a successor. Health systems in leadership transition frequently see downstream effects on embedded specialty programs — staffing changes, shifting protocols, even changes to how a program reports its outcomes. This isn't a reason to avoid hospital-affiliated fertility programs, but it is a reason to look at multi-year SART trends rather than a single reporting year, and to ask directly whether the clinic's leadership or ownership has changed recently. A single strong year under outgoing leadership can be a poor predictor of what your cycle looks like eighteen months from now. This is the same instability dynamic I cover in how a 30-point SART gap and hospital consolidation should change your clinic decision.

Rising premiums are eating the self-pay budget too

Healthcare workers themselves are increasingly going uninsured as ACA premiums climb — one Idaho couple, both practitioners fully aware of the medical risk, chose to drop coverage entirely because the monthly cost became unsustainable. If people trained to weigh medical risk are making that trade-off, it's worth checking your own premium trajectory before you lock in a multi-cycle plan. A $300–$500 monthly premium increase over a two-cycle treatment window is another $3,600–$6,000 you didn't budget for, on top of the clinic quote. If you're paying cash for treatment regardless of coverage, and considering IVF abroad as a lower-cost alternative, it's also worth noting that Chase recently dropped the foreign transaction fee on its Freedom Flex card — a small detail, but it matters if you're paying international clinics or pharmacies directly and want to avoid an extra 3% tax on every charge.

What to actually do before your next cycle

Don't compare clinics on price alone, and don't compare them on a single-year success rate alone. Pull each clinic's SART data filtered to your specific age band and diagnosis, calculate the cumulative probability across the number of cycles you're realistically willing to fund, and divide your total projected spend by that cumulative probability — not by one cycle's cost. Add a denial-contingency buffer given how routinely insurers fight claims after the fact, and check whether your Medicaid exemption status or premium situation has shifted in the last few months.

You built one spreadsheet already just getting this far. Let Feralyx build the next one — with your age, your diagnosis, your insurance situation, and the clinics you're actually choosing between, so the number you're deciding on is the real one.

Sources

• New lawsuit targets Medicaid work requirements’ medical frailty rules — Healthcare Dive
• As Health Insurance Costs Soar, Healthcare Workers Also Feel the Pinch — KFF Reproductive Health
• Hackensack Meridian Health CEO to retire next year — Healthcare Dive
• Texas hospitals sue Independence Blue Cross over denied claims — Healthcare Dive
• Chase Freedom Flex Ditches Foreign Transaction Fee, Cell Phone Insurance — NerdWallet Health